7
Clinical governance, ethics and medicolegal aspects of endocrine surgery
Clinical governance
We are in the third health revolution. The first was the arrival of technology to improve care, the second the impact of financial constraints and the third the era of accountability.1 The measurement and regulation of clinical activity is here to stay.
There is ample evidence that doctors left to their own devices are not as effective as they would like to think they are, and never have been. Most surgeons would agree that unacceptable variations in standards of care and outcomes must be made to disappear yet, despite good intentions, therapeutic activity that is ineffective or unsubstantiated may take many years to disappear from clinical practice. In addition, our individual practice and the interventions that we use inevitably reflect the current fashion, sometimes in the absence of any evidence base. In contrast, we should not lose sight of the fact that the ‘evidence base’ and systematic reviews may be adversely affected by subjective analysis, interpretations of variations in the results from previous studies, publication bias and missing data. In ideal circumstances, from an idea and hypothesis that leads to technical advances in surgery there should be systematic progression that ends in the development and assessment of appropriate outcome measures.2 This certainly applies to the development of minimally invasive surgery of the thyroid and parathyroid glands.3 Are mortality and readmission rates, complications and duration of hospital stay sufficient to show that the new is an improvement on what has gone before?
• Do all patients with retrosternal goitre require surgery?
• Radioiodine or surgery for patients with thyrotoxicosis?
• The extent of surgery for differentiated thyroid cancer?
• Prophylactic lymph node dissection in papillary thyroid cancer?
• The extent of lymph node surgery in medullary thyroid cancer?
• When to complete primary surgery/re-operate in patients with medullary thyroid cancer?
• The indications for surgery in patients with mild hypercalcaemia?
• What are the indications for re-operative parathyroid surgery?
• Which imaging studies are appropriate prior to re-operative surgery?
• Transperitoneal or retroperitoneal laparoscopic surgery?
• Open or laparoscopic surgery in patients with Stage 1 or 2 adrenocortical cancer?
• What size of incidentaloma should be removed?
• Which preoperative localisation/regionalisation studies are required in patients with insulinoma/gastrinoma?
• When to operate on the pancreas and the extent of surgery in patients with multiple endocrine neoplasia type 1 (MEN1)?
Various international guidelines, consensus/positional statements are available to guide good practice in the investigation and surgical treatment of adult and paediatric4 thyroid (thyrotoxicosis,5 benign nodules, differentiated and medullary thyroid cancer6–8), parathyroid (hyperparathyroidism9,10) and adrenal (incidentaloma,11 malignant tumours12) disease.
Guidelines should help us make decisions about what is appropriate and, in association with a review of whatever evidence there is, lead to change and improvement in patient care. It should be remembered that guidelines are ‘explicit’ information that helps us to make decisions, but the art of medicine needs as much ‘tacit’ as ‘explicit’ input.13 Written statements describing the rules, actions and conditions that direct patient care can be considered as a medical definition of standards of care.
What is good practice?
• Which biochemical/cytological tests and imaging studies are necessary prior to surgery, and will their results alter the management of the patient?
• Is an operation required? What is the purpose and aim of the procedure? How will this benefit the patient?
• Which operation is appropriate in this specific case?
• Does the patient understand the indications, implications and risks of surgery in order to give informed consent?
Who should perform surgery on the endocrine glands?
The 1996 consensus statement on thyroid disease by the Royal College of Physicians of London and Society of Endocrinology14 stated: ‘each District General Hospital should have access to an experienced thyroid surgeon’. Although surgery of the endocrine glands is currently the scene of dispute between general surgeons (endocrine/upper gastrointestinal/hepatobiliary), head and neck, oromaxillofacial, ENT surgeons and urologists, no individual group has an unassailable right to care for and treat the patients. The needs of the patient must come first. The introduction to the British Association of Endocrine and Thyroid Surgeons (BAETS) guidelines15 states:
The advantages of subspecialisation
It is all too easy to lose sight of the important issues:
• one or more surgeons with a declared interest in endocrine surgery;
• an annual operative workload in excess of 50 cases (verified by BAETS audit);
• on-site cytology and histopathology services;
• at least one consultant endocrinologist on site, holding one or more dedicated endocrinology clinics per week, with joint clinics or formal meetings held not less than once per month;
• a Department of Nuclear Medicine on site;
• on-site magnetic resonance imaging (MRI) and computed tomography (CT) scanning.
The current syllabus (www.iscp.ac.uk/documents/syllabus_GS_2010.pdf) and subspecialist curriculum (www.baes.info/Pages/BAETS%20Guidelines.pdf) for endocrine surgical training in the UK are well defined. Examples of how endocrine surgical operative experience and competence for an individual trainee can be identified and rated (www.nthst.org.uk/Assets/Files/RITA_forms/NTHST_OpComp_Endocrine_v_1.doc) are available, and in future will help define what constitutes ‘appropriately trained’.
Complication rates following thyroid, parathyroid and adrenal procedures are higher in patients treated by non-specialists, and lower when ‘high-volume’ surgeons operate or patients are treated in high-volume centres.16–20 This is also true for paediatric endocrine surgery.21,22 Supervised trainees and newly established endocrine surgeons can perform thyroid surgery safely.23–25
There is evidence from the UK and the USA to support a continued need for subspecialisation in endocrine surgery and adherence to good practice, e.g. total thyroidectomy and lymph node dissection is the standard of care in patients with medullary thyroid cancer (MTC) yet 10–15% of patients with MTC undergo less than total thyroidectomy and 30–40% of patients have no cervical node dissection.26–29 MTC is rare; all patients should be referred for surgical treatment to a cancer centre.
3. As the quality of the care received by the patient is paramount it should be subject to assessment by audit and benchmarking against agreed standards.
In 1998, a retrospective study from a single district hospital identified that only 42% of patients with thyroid cancer presenting with a thyroid nodule had preoperative fine-needle aspiration cytology (FNAC).30 In contrast, BAETS audit data from 2009 reported that 82% of treated patients, confirmed at histology to have a neoplastic lesion, underwent fine-needle aspiration (FNA) prior to the operation.29 The collection of such prospective information on endocrine surgical activity in the UK is crucial, not only for issues of surgical subspecialisation but for education and training. For UK surgeons, continuing full membership of the BAETS is conditional upon the submission of their clinical activity to the audit. It is likely in the future that General Medical Council (GMC) revalidation will require confirmation that surgeons take part in comparative national audit. The following standards and outcome measures are suggested as being applicable to current endocrine surgical practice.
Thyroid surgery
• The indications for operation, risks and complications should be discussed with patients prior to surgery.
• FNAC should be performed routinely in the investigation of solitary thyroid nodules.
• The recurrent laryngeal nerve should be routinely identified in patients undergoing thyroid surgery.
• All patients scheduled for re-operative thyroid surgery should undergo preoperative examination of their vocal cords by an ENT surgeon. All patients reporting voice change after thyroid surgery should undergo examination of their vocal cords. Permanent vocal cord palsy should not occur in more than 1% of patients.
• A return to theatre to control postoperative haemorrhage should occur in less than 5% of patients.
• All patients with thyroid cancer should be reviewed by the Cancer Centre designated specialist multidisciplinary team.
Outcome measures: There should be documented evidence to support that:
• The patient was informed of the indications for surgery and its risks and complications.
• FNAC was performed in at least 90% of patients prior to operation for solitary/dominant nodule.
• The recurrent laryngeal nerve(s) were identified during a surgical procedure.
• The permanent postoperative vocal cord palsy rate is not more than 1%.
• All patients scheduled for re-operative thyroid surgery have undergone preoperative examination of their vocal cords.
• The re-operation rate for postoperative haemorrhage after thyroidectomy is less than 5%.
• Patients with thyroid malignancy have been reviewed by the specialist multidisciplinary team.
Parathyroid surgery
Standards: In patients who undergo first-time operation for primary hyperparathyroidism:
• The indications for operation, risks and complications should be discussed with patients prior to surgery.
• The surgeon should identify and cure the cause of the disease in at least 95% of cases.
• All patients reporting voice change after parathyroid surgery should undergo examination of their vocal cords. Permanent vocal cord palsy should not occur in more than 1% of patients.
• All patients scheduled for re-operative parathyroid surgery should undergo preoperative examination of their vocal cords.
• Permanent hypocalcaemia should not occur in more than 5% of patients.
Outcome measures: There should be documented evidence to support that:
• The patient was informed of the indications for surgery and its risks and complications.
• After first-time parathyroid surgery, at least 90% of patients are normocalcaemic without calcium or vitamin D supplements.
• The permanent postoperative vocal cord palsy rate is not more than 1%.
• All patients scheduled for re-operative parathyroid surgery have undergone preoperative examination of their vocal cords.
Adrenal surgery
Standards: There should be multidisciplinary working to agreed diagnostic and therapeutic protocols to ensure that an appropriate strategy is developed for patients. This should include the management of the preoperative, perioperative and postoperative metabolic syndrome.
Pancreatic surgery
• There should be multidisciplinary working to agreed diagnostic and therapeutic protocols to ensure that an appropriate strategy is developed for patients. This should include management of the preoperative, perioperative and postoperative metabolic syndrome.
• Patients with familial endocrine disease should be identified prior to surgery.
• The aims of any surgical procedure must be clearly defined prior to surgery.
Medicolegal aspects of endocrine surgery
Consent
A formal process of consent in surgery is essential as it is that consent that renders surgical intervention legal. Consent requires that the patient has the capacity to understand the process,31 has the information about the nature and the purpose of the surgery to allow informed consent, and provides consent voluntarily. Failure to respect these principles means that there was effectively no consent, and the doctor is therefore open to charges of battery or to a claim of negligence. Negligence is the failure to take reasonable care.
In the hallmark UK case of Sidaway, Lord Justice Dunn said that ‘the concept of informed consent forms no part of English law’.32 There is no explicit legal meaning to the term ‘informed consent’ used by doctors. The case of Sidaway involved a patient who experienced spinal cord complications after an operation on a cervical vertebra as treatment for nerve root pain. She had not been informed about this particular rare complication when she gave her consent, and she claimed that she would not have had the operation if more information had been available. In this case, the patient was not warned because the neurosurgeon judged the risk to be remote, i.e. less than 1%. The problem highlights the potential gap between the ‘patient standard’, which is what the patient might wish to know, and the ‘professional standard’, which is what the doctor thinks the patient ought to or needs to know. Patients who experience a complication from an operation will, with the wisdom of hindsight, wish they had been told about a rare but damaging complication, whereas surgeons might reasonably not tell patients of all potential risks that could occur.
In the matter of consent (as in most other medico-legal issues), case law in England and Scotland tends to reflect the application of the ‘Bolam test’ (see below), namely that the information that the surgeon needs to give is the information that a reasonable and responsible member of the medical profession would think it proper to give in the circumstances. The amount of information that is given to validate ‘informed’ consent is not defined in law. The rule of thumb is that it should be any risk that is likely to occur in more than 1–2% of cases, but it is important to remember that the quality of information given for consent in medical care is an ethical not a legal requirement of a doctor and is to do with the respect for the autonomy of the patient.33 Sidaway puts the onus on doctors to decide what information to give; the ethical requirement is merely to give what the doctors’ best judgment of each patient defines as the patient’s need, and to give it in terms appropriate to the patient’s understanding and their education. This trend is also likely to be encouraged by the Council of Europe’s Convention on Human Rights: Biomedicine, 1997, which explicitly notes the ‘need to restrain the paternalist approaches which might ignore the wishes of the patient’.34 It is better to look at the process of ‘informed’ consent as part of a shared decision- making process, founded in adult debate with patients about the management of their disease. The risks and consequences of various treatment options should be discussed in sufficient detail to be understood so that patients can make informed decisions. In practical terms the surgeon, or somebody who is familiar with the disease and its treatment, must sign the consent form together with the patient. We recommend the use of patients’ information sheets (as illustrated in the BAETS Guidelines), but remember that their use does not obviate the need for detailed personal discussions between patients and surgeons (Box 7.1). Key issues to consider in risk management with regard to matters of consent include keeping contemporaneous notes of conversations held with patients about consent and knowledge that a signed consent form is not in itself enough to demonstrate that a patient gave valid/informed consent.
When things do not go smoothly
Only a tiny percentage of problems and errors mature into a complaint. Errors can occur without associated complications and we should be aware that complications may arise without errors as well as a result of errors. It is clear that if complaints are handled effectively and promptly, and if there is good and honest communication of facts, the number of complaints that mature into litigations are few. One of the virtues of proper handling of complaints is that they often show that although things did not turn out for the best, the problems that occurred were within the boundaries of those experienced in medical care and were not a sign of negligence. It is much more common for complaints to reflect a sequence of unsatisfactory events in the patient’s care and in 72% of instances a perception of staff insensitivity or a communication breakdown is the element that precipitates the complaint.35 Other factors that may precipitate a complaint include failure to investigate or treat (25%) and a claim of lack of clinical competence (20%).
Complaints that turn into litigation
In the UK, formal claims under the Clinical Negligence Scheme for Trusts increased by 31% in 2009/10. In 2010/11 the National Health Service Litigation Authority (NHSLA) paid out more than £863 000 000 in respect of clinical negligence claims. Between April 2001 and March 2011, 63 804 claims for medical negligence files were opened: 38% were abandoned by the claimant, 45% were settled out of court, in 3% damages were approved/set by the court and the remainder were yet to settle.36
In 1993, Kern identified for analysis 62 cases of malpractice related to the surgical treatment of endocrine disease from 21 North American states between 1985 and 1991. In 54% of instances the problem arose from a surgical complication, almost all during thyroid surgery; 35% arose from delayed diagnosis, equally of thyroid and adrenal disease; and 11% were from morbidity attributed to radioiodine or propylthiouracil.37 A more recent review38 of cases from the North American LexisNexis Academic Legal database identified court reports of 33 medical malpractice cases involving thyroid surgery between 1989 and 2009; 46% involved injury to the recurrent laryngeal nerve. Most of the cases filed involved the adequacy of the consent process; the maximum jury award to a plaintiff was $3.7 million. In most cases that favoured the patient, although a consent form was signed it was felt that insufficient discussion took place with regard to the potential risks of surgery. The number of cases settled out of court during the same time period is unknown.38 The estimated incidence of malpractice claims in thyroid surgery in the USA is 5.9 cases per 10 000 operations.39
Medical negligence
1. A relationship must exist between the parties (the surgeon and the patient), which gives rise to a duty of care.
2. The duty of care must have been breached in some way due to an unreasonable act or omission by one of the parties. This breach of the duty of care is the negligence.
3. In addition to the negligence the injured party must have experienced some damage, loss or injury of a type recognised by the law.
4. The damage must have been caused by the other party, in this case the surgeon.
5. The action must be brought within a specified time after the injury has occurred (this is known as the period of limitation; see above).
Duty of care: As the NHS surgical patient will already have come under the care of a hospital, either as an outpatient or inpatient, the plaintiff will have no difficulty in establishing that the hospital Trust has a duty of care. In private practice (and this includes patients admitted to NHS pay beds) the relationship is primarily directly with the surgeon and separately with the other providers, such as the hospital, anaesthetist, pathology laboratory, etc. The duty of care in this latter situation arises through the ‘contract’ that arises implicitly between the surgeon and patient.
Breach of duty of care: The legal definition of a standard of care might include ‘the watchfulness, attention, caution and prudence that a reasonable person in the circumstances would exercise’.
Bolam is the legal case cited in England.40 In Scotland it is Hunter v. Hanley.41 Essentially these cases have the same conclusion, which is generally favourable to the surgeon.
The case of Bolitho v. City and Hackney Health Authority slightly changed the principles behind the Bolam judgment.42 Medical evidence from eight experts was divided. The judge accepted that both bodies of evidence were respectable and concluded that he was in no position to ‘prefer’ one view. This was in line with Lord Scarman’s view in another case that: ‘a judge’s preference for one body of distinguished opinion over another, also professionally distinguished, is not sufficient to establish negligence in a practitioner’.43
Damage
Causation: Letters from solicitors will often use the term ‘causation’, a term not immediately understood by doctors (Box 7.2). In the legal setting ‘causation’ is merely the establishment of a factual and legal link between the breach of duty and the damage caused. This is often difficult to prove. Normally the ‘but for’ test is used. For example, ‘but for the failure to take a fine-needle biopsy at the first outpatient visit the patient’s thyroid carcinoma would have been diagnosed 6 months earlier’. Note that in negligence cases guilt or innocence is decided on grounds of ‘balance of probability’ rather than ‘beyond reasonable doubt’, as applies in criminal cases.
Expert opinions
• The report is addressed to the court.
• It contains a statement that experts understand that their duty is to the court.
• Experts may if they wish file a written request to the court for directions to assist them in carrying out their function as an expert. They do not need to give the claimant, defendant or the instructing solicitor any notice of such a request.
A useful brief guide for clinicians on the possible outcome of events in clinical negligence litigation is available at http://www.nhsla.com/Claims/Pages/Advice.aspx.
Ethical issues in the use of new technology in endocrine surgery
As noted in the prior sections, the central ethical issue in the practice of endocrine surgery, as in the practice of all aspects of surgery, is to ensure that patients have adequate information about the risks, benefits and alternatives to surgery so that they can give adequate informed consent. When a new device or a new procedure is being offered to a patient, the challenges of obtaining informed consent are increased. Often there are few data about the outcomes of the new procedure. Communicating this uncertainty about results to patients can be very challenging. Furthermore, surgeons often have much less experience with new devices or new approaches to an operation.44 Honest communication of a surgeon’s lack of experience with a new procedure is critical to true informed consent for such a procedure.
A final ethical issue that arises in the use of new technology and innovation in endocrine surgery is the problem of overstating the value of the new device to patients. A perfect example of this can be seen in much of the discussion surrounding the use of neuromonitoring technology to reduce recurrent laryngeal nerve (RLN) injuries. There is no ethical issue associated with the use or non-use of neuromonitoring in thyroid and parathyroid surgery since the data do not show a significant reduction in permanent RLN injuries with use of the neuromonitor. A careful surgeon with good results may choose to use or not to use the device. However, the ethical issue arises when a surgeon makes the claim that use of the technology will eliminate the risk of RLN injury.45 Since such a claim is not supported by the evidence, to present this claim to patients is clearly misleading and unethical.
Conclusions
Effective clinical governance will help define:
• the appropriateness and effectiveness of our interventions;
• the lack of evidence that supports some of our current practice;
Complaint and litigation will not go away. An increase in individualism, loss of respect for professionals, more mechanical medical processes and a good supply of well-trained, proficient lawyers is going to ensure that whatever the changes in legislation and clinical practice, litigation will continue. Risk reduction activity by surgeons should include the routine practice of documenting that an appropriate consent process has occurred and the use of patient information material. Write thorough and legible notes. When a patient’s condition deteriorates the surgeon should seek help early if complications occur, be sympathetic and refer the patient to an appropriate specialist for management of the complication.38,47 Adherence to protocols, competence-based training and career-long postgraduate education should aim to reduce the incidence of harm to the unavoidable minimum. Complaints that are not satisfactorily resolved may be better handled by processes of arbitration or mediation rather than the traditional confrontationalism of the legal process. The legal aid process is already attempting to weed out such cases.
References
1. Relman, A.S., Assessment and accountability: the third revolution in medical care. N Engl J Med. 1988;319(18):1220–1222. 3173460
2. Lorenz, W., Troidl, H., Solomkin, J.S., et al, Second step: testing outcome measurements. World J Surg. 1999;23(8):768–780. 10415201
3. Miccoli, P., Minimally invasive surgery for thyroid and parathyroid diseases. Surg Endosc. 2002;16(1):3–6. 11961594
4. Spoudeas, H. Paediatric endocrine tumours. A Multi-Disciplinary Consensus Statement of Best Practice from a Working Group Convened Under the Auspices of the BSPED and UKCCSG (rare tumour working groups). Available from http://www.bsped.org.uk/clinical/docs/RareEndocrineTumour_final.pdf, 2005. [[accessed 9.07.12]].
5. Bahn, R.S., Cooper, D.S., Garber, J.R., et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Available from https://www.aace.com/files/hyper-guidelines-2011.pdf, 2011.
6. British Thyroid Association Royal College of Physicians. Guidelines for the management of thyroid cancer. Available from http://www.british-thyroid-association.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf, 2007. [[accessed 9.07.12]].
7. Cooper, D.S., Doherty, G.M., Haugen, B.R., et al, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. 19860577
8. Kloos, R.T., Eng, C., Evans, D.B., et al, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612. 19469690
9. Bergenfelz, A.O., Hellman, P., Harrison, B., et al, Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbecks Arch Surg. 2009;394(5):761–764. 19575214
10. Bilezikian, J.P., Khan, A.A., Potts, J.T., Jr., Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–339. 19193908
11. Zeiger, M.A., Thompson, G.B., Duh, Q.Y., et al, The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl. 1):1–20. 19632967
12. Henry, J.F., Peix, J.L., Kraimps, J.L., Positional statement of the European Society of Endocrine Surgeons (ESES) on malignant adrenal tumors. Langenbecks Arch Surg. 2012;397(2):145–146. 22203016
13. Wyatt, J.C., Management of explicit and tacit knowledge. J R Soc Med. 2001;94(1):6–9. 11220080
14. Vanderpump, M.P., Ahlquist, J.A., Franklyn, J.A., et al, Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Br Med J. 1996;313(7056):539–544. 8789985
15. British Association of Endocrine Surgeons. Guidelines for the surgical management of endocrine disease and training requirements for endocrine surgery. Available from http://www.baets.org.uk/Pages/BAETS%20Guidelines.pdf, 2004. [[accessed 9.07.12]].
16. Sosa, J.A., Bowman, H.M., Tielsch, J.M., et al, The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–330. 9742915
17. Stavrakis, A.I., Ituarte, P.H., Ko, C.Y., et al, Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 2007;142(6):887–899. 18063073
18. Mitchell, J., Milas, M., Barbosa, G., et al, Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery. 2008;144(6):899–907. 19040995
19. Pieracci, F.M., Fahey, T.J., 3rd., Effect of hospital volume of thyroidectomies on outcomes following substernal thyroidectomy. World J Surg. 2008;32(5):740–746. 18200430
20. Park, H.S., Roman, S.A., Sosa, J.A., Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144(11):1060–1067. 19917944
21. Wang, T.S., Roman, S.A., Sosa, J.A., Predictors of outcomes following pediatric thyroid and parathyroid surgery. Curr Opin Oncol. 2009;21(1):23–28. 19125014
22. Tuggle, C.T., Roman, S.A., Wang, T.S., et al, Pediatric endocrine surgery: who is operating on our children? Surgery. 2008;144(6):869–877. 19040991
23. Hassan, I., Koller, M., Kluge, C., et al, Supervised surgical trainees perform thyroid surgery for Graves’ disease safely. Langenbecks Arch Surg. 2006;391(6):597–602. 16955302
24. Sywak, M.S., Yeh, M.W., Sidhu, S.B., et al, New surgical consultants: is there a learning curve? Aust N Z J Surg. 2006;76(12):1081–1084. 17199694
25. Erbil, Y., Barbaros, U., Issever, H., et al, Predictive factors for recurrent laryngeal nerve palsy and hypoparathyroidism after thyroid surgery. Clin Otolaryngol. 2007;32(1):32–37. 17298308
26. Kebebew, E., Greenspan, F.S., Clark, O.H., et al, Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890–896. 15922202
27. Roman, S., Lin, R., Sosa, J.A., Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–2142. 17019736
28. Panigrahi, B., Roman, S.A., Sosa, J.A., Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol. 2010;17(6):1490–1498. 20224861
29. British Association of Endocrine and Thyroid Surgeons 3rd National Audit Report. Dendrite Clinical Systems. Oxfordshire: Henley on Thames; 2009.
30. Vanderpump, M.P., Alexander, L., Scarpello, J.H., et al, An audit of the management of thyroid cancer in a district general hospital. Clin Endocrinol (Oxf). 1998;48(4):419–424. 9640408
31. Nicholson, T.R., Cutter, W., Hotopf, M., Assessing mental capacity: the Mental Capacity Act. Br Med J. 2008;336(7639):322–325. 18258967
32. Brahams, D., The surgeon’s duty to warn of risks: transatlantic approach rejected by Court of Appeal. Lancet. 1984;1(8376):578–579. 11644281
33. Davies, M. Textbook on medical law. London: Blackstone Press; 1996. [p. 166–74].
34. . Medical Law Monitor. 1997;4(10):6.
35. Bark, P., Vincent, C., Jones, A., et al, Clinical complaints: a means of improving quality of care. Qual Health Care. 1994;3(3):123–132. 10139408
36. The NHS Litigation Authority Factsheet 3: information on claims. Available from http://www.nhsla.com/CurrentActivity/Documents/NHSLA Factsheet 3-claims information 2011-12.doc
37. Kern, K.A., Medicolegal analysis of errors in diagnosis and treatment of surgical endocrine disease. Surgery. 1993;114(6):1167–1174. 8256224
38. Abadin, S.S., Kaplan, E.L., Angelos, P., Malpractice litigation after thyroid surgery: the role of recurrent laryngeal nerve injuries, 1989–2009. Surgery. 2010;148(4):718–723. 20709343
39. Singer, M.C., Iverson, K.C., Terris, D.J., Thyroidectomy-related malpractice claims. Otolaryngol Head Neck Surg. 2012;146(3):358–361. 22217914
40. Bolam v. Friern Hospital Management Committee. [1957] 1 WLR 582.
41. Hunter v. Hanley. [1955] SLT 213.
42. Bolitho v. City and Hackney Health Authority. [1997] 4 All ER 771.
43. Maynard v. West Midlands Regional Health Authority. [1985] 1 All ER 635.
44. Angelos, P., The ethical challenges of surgical innovation for patient care. Lancet. 2010;376(9746):1046–1047. 20879091
45. Angelos, P., Recurrent laryngeal nerve monitoring: state of the art, ethical and legal issues. Surg Clin North Am. 2009;89(5):1157–1169. 19836490
46. Hayward, R., The shadow-line in surgery. Lancet. 1987;1(8529):375–376. 2880174
47. Sokol, D.K., How can I avoid being sued? Br Med J 2011; 343:d7827. 22171348